Empowering self-treatment to tackle cardiometabolic diseases
In the latest issue of Pharmaceutical Manufacturing and Packing Sourcer, SHL Medical provides insights into how our innovative drug delivery solutions and scalable manufacturing expertise make us as the ideal device partner for novel cardiometabolic compounds.
With global obesity rates exceeding 1 billion and projected to reach 1.9 billion by 2035, the need to tackle obesity and its related cardiometabolic diseases has never been more urgent. The rise of novel GLP-1RA molecules further underscores the need for reliable and scalable solutions from device manufacturers to meet the growing demand for advanced drug-device projects.
In particular, the article spotlights SHL Medical’s Molly® autoinjectors, which have been instrumental in bringing second-generation GLP-1RAs to market. Successfully supporting the approval of combination products indicated for type 2 diabetes in 2020 and obesity in 2021, Molly’s modular platform technology stands out for its scalability and adaptability to meet various market needs. By offering rapid device development options, Molly is the ideal choice to support the rapidly growing cardiometabolic care market.
SHL’s commitment to patient-centricity is evident through its continuous effort to improve patients’ experience. The article describes SHL’s extensive studies to ensure consistent autoinjector performance across differing fat distributions. With proven device technologies, scalable manufacturing capabilities, and a dedication to enhancing patients’ experience, SHL Medical stands out as the ideal device partner to support the advancement of future therapeutic innovations.
